Cargando…
Osteoporosis prevention among chronic glucocorticoid users: results from a public health insurance database
INTRODUCTION: Long-term glucocorticoid therapy is the leading cause of secondary osteoporosis. The management of glucocorticoid-induced osteoporosis (GIOP) seems to be inadequate in many European countries. OBJECTIVE: To evaluate the rate of screening and treatment of GIOP. DESIGN: Information was c...
Autores principales: | Trijau, Sophie, de Lamotte, Gaëlle, Pradel, Vincent, Natali, François, Allaria-Lapierre, Véronique, Coudert, Hervé, Pham, Thao, Sciortino, Vincent, Lafforgue, Pierre |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947732/ https://www.ncbi.nlm.nih.gov/pubmed/27486526 http://dx.doi.org/10.1136/rmdopen-2016-000249 |
Ejemplares similares
-
Glucocorticoid-induced osteoporosis
por: Briot, Karine, et al.
Publicado: (2015) -
Vertebral fracture risk in glucocorticoid-induced osteoporosis: the role of hypogonadism and corticosteroid boluses
por: Florez, Helena, et al.
Publicado: (2020) -
Denosumab Versus Risedronate in Glucocorticoid‐Induced Osteoporosis: Final Results of a Twenty‐Four–Month Randomized, Double‐Blind, Double‐Dummy Trial
por: Saag, Kenneth G., et al.
Publicado: (2019) -
Osteoporosis : fisiopatología, diagnóstico, prevención y tratamiento /
por: Zanchetta, José R.
Publicado: (2001) -
Convivir con la osteoporosis /
por: Díaz Curiel, Manuel
Publicado: (2004)